BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
57.77
+1.02 (1.80%)
Sep 5, 2025, 4:00 PM - Market closed

BioMarin Pharmaceutical Stock Forecast

Stock Price Forecast

The 22 analysts that cover BioMarin Pharmaceutical stock have a consensus rating of "Buy" and an average price target of $93.14, which forecasts a 61.23% increase in the stock price over the next year. The lowest target is $65 and the highest is $126.

Price Target: $93.14 (+61.23%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$65$93.14$90$126
Change+12.52%+61.23%+55.79%+118.11%
* Price targets were last updated on Aug 6, 2025.

Analyst Ratings

The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingApr '25May '25Jun '25Jul '25Aug '25Sep '25
Strong Buy566676
Buy111010111111
Hold666666
Sell000000
Strong Sell000000
Total222222232423

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Guggenheim
Guggenheim
Strong Buy
Maintains
$101$106
Strong BuyMaintains$101$106+83.49%Aug 6, 2025
UBS
UBS
Strong Buy
Maintains
$113$114
Strong BuyMaintains$113$114+97.33%Aug 5, 2025
Morgan Stanley
Morgan Stanley
Buy
Maintains
$97$96
BuyMaintains$97$96+66.18%Jul 22, 2025
JP Morgan
JP Morgan
Buy
Maintains
$108$113
BuyMaintains$108$113+95.60%Jul 14, 2025
Goldman Sachs
Goldman Sachs
Strong Buy
Maintains
$124$104
Strong BuyMaintains$124$104+80.02%May 5, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
3.23B
from 2.85B
Increased by 13.32%
Revenue Next Year
3.54B
from 3.23B
Increased by 9.37%
EPS This Year
3.49
from 2.21
Increased by 58.08%
EPS Next Year
4.45
from 3.49
Increased by 27.41%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.86B1.85B2.10B2.42B2.85B3.23B3.54B
Revenue Growth
9.18%-0.76%13.53%15.42%17.97%13.32%9.37%
EPS
4.50-0.350.750.872.213.494.45
EPS Growth
---16.00%153.71%58.08%27.41%
Forward PE
-----16.5612.99
No. Analysts
-----3029
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High3.4B3.9B
Avg3.2B3.5B
Low3.0B3.1B

Revenue Growth

Revenue Growth20252026202720282029
High
18.3%
20.3%
Avg
13.3%
9.4%
Low
5.8%
-3.1%

EPS Forecast

EPS20252026202720282029
High4.385.58
Avg3.494.45
Low2.503.16

EPS Growth

EPS Growth20252026202720282029
High
98.4%
59.8%
Avg
58.1%
27.4%
Low
13.2%
-9.6%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.